Pieris Pharmaceuticals, Inc.

符号: PIRS

NASDAQ

11.08

USD

今天的市场价格

-0.5788
市盈率
0.0000
PEG比率
13.70M
MRK市值
0.00%
DIV收益率

Pieris Pharmaceuticals, Inc. (PIRS) 财务报表

Q: 什么是 Pieris Pharmaceuticals, Inc. (PIRS) 总资产是多少？

Pieris Pharmaceuticals, Inc. (PIRS) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 Pieris Pharmaceuticals, Inc. (PIRS). 的默认数据。公司收入显示 23.101 M 的平均值，即 0.394 % 增长率。整个期间的平均毛利润为 13.473 M，即 0.403 %. 平均毛利率为 0.751 %. 公司去年的净收入增长率为 -0.215 %，等于 -13.751 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 Pieris Pharmaceuticals, Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 -0.595. 在流动资产领域，PIRS 的报告货币为38.68. 这些资产中的很大一部分，即 26.366 是现金和短期投资。与去年的数据相比，该部分的变化率为-0.554%. 公司的长期投资虽然不是其重点，但以报告货币计算的0（如果有的话）为0。这表明与上一报告期相比，0.000% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 0. 这一数字表明，-1.000% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 26.758. 这方面的年同比变化率为 -0.042%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为6.039，存货估值为 0，商誉估值为 0（如有. 无形资产总额（如果有）按 0 估值.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
balance-sheet.row.cash-and-short-term-investments	174.43	26.4	59.2	117.8	70.4	104.2	128.1	72.6	29.4	29.3	18.5	3.7
balance-sheet.row.short-term-investments	39.46	9	20.5	0	0	41.9	53.2	34.8	0	0	0	0
balance-sheet.row.net-receivables	11.07	6	5.8	3.3	1.7	6.8	2.7	15.5	0.1	0	0	0.5
balance-sheet.row.inventory	2.1	0	0	0	0	0	0	0	0	0	0	0.1
balance-sheet.row.other-current-assets	37.14	6.3	8.4	6.5	3.6	4.1	4.6	1.6	3.3	2.3	1.3	0.5
balance-sheet.row.total-current-assets	224.75	38.7	73.4	127.6	75.7	115	135.4	89.8	32.7	31.7	19.8	4.8
balance-sheet.row.property-plant-equipment-net	42.47	0	20.7	23	26	22.9	5	4	2.3	2.2	2.1	2.4
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.goodwill-and-intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-investments	0	0	0	0	0	0	0	9.9	0	0	0	0
balance-sheet.row.tax-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	0.65	0	1.4	2.9	3.3	3.1	0.9	0.1	0.1	0.1	0	0
balance-sheet.row.total-non-current-assets	43.11	0	22.1	25.9	29.3	26.1	6	14.1	2.4	2.3	2.1	2.5
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	267.86	38.7	95.5	153.6	105	141.1	141.3	103.9	35.1	34	21.9	7.3
balance-sheet.row.account-payables	22.5	3.4	4.2	8.6	3	10.1	3.4	2.5	2.4	1.1	1.3	0.3
balance-sheet.row.short-term-debt	14.09	0	0.9	1	1	0.7	0	4.9	0	0	1.3	0.2
balance-sheet.row.tax-payables	0	0	0	0	0.1	0.5	0.4	0.4	0.5	0.2	0	0
balance-sheet.row.long-term-debt-total	24.12	0	12.2	13.8	15.9	15.5	0	0	0	0	0	4.5
Deferred Revenue Non Current	12.49	0	18.7	38.4	35.9	47.3	53.3	46.5	1.4	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	-12.49	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	36.07	8.6	10.7	15.8	5.5	5	9.1	1.3	3.7	1.7	0.2	0.7
balance-sheet.row.total-non-current-liabilities	36.6	0	31	52.2	51.8	62.7	53.3	46.6	1.5	0	0.3	4.9
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	37.32	0	12.2	13.8	17	16.2	0	0	0	0	0	0
balance-sheet.row.total-liab	154.63	11.9	67.6	102.8	74	89.7	101.4	92.4	9.8	2.8	3.9	6.7
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	0.37	0.1	0.1	0.1	0.1	0.1	0.1	0	0	0	0	0
balance-sheet.row.retained-earnings	-1228.58	-315	-290.4	-257.1	-211.4	-174.2	-147.1	-120.3	-102.7	-79.9	-65.8	-56
balance-sheet.row.accumulated-other-comprehensive-income-loss	-0.87	0	-0.3	0.8	-0.3	-2	-3	-4.7	-1.5	-1.3	-0.8	-1
balance-sheet.row.other-total-stockholders-equity	1342.3	341.6	318.5	307	242.7	227.5	189.9	136.5	129.3	112.2	84.6	57.5
balance-sheet.row.total-stockholders-equity	113.22	26.8	27.9	50.8	31	51.4	39.9	11.5	25.2	31.1	18	0.6
balance-sheet.row.total-liabilities-and-stockholders-equity	267.86	38.7	95.5	153.6	105	141.1	141.3	103.9	35.1	34	21.9	7.3
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	113.22	26.8	27.9	50.8	31	51.4	39.9	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	267.86	-	-	-	-	-	-	-	-	-	-	-
Total Investments	39.46	9	20.5	0	0	41.9	53.2	44.7	0	0	0	0
balance-sheet.row.total-debt	37.32	0	13.1	13.8	17	16.2	0	0	0	0	1.3	4.8
balance-sheet.row.net-debt	-97.65	-17.4	-25.5	-103.9	-53.5	-46	-74.9	-37.9	-29.4	-29.3	-17.2	1.1

现金流量表

在 Pieris Pharmaceuticals, Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 0.115 的转变。该公司最近通过发行 19.8 扩大了股本，与上一年相比出现了32.432 的差异. 公司的投资活动产生了现金使用净额，按报告货币计算达到12002000.000. 与上一年相比， -1.565 发生了变化. 在同一时期，公司记录了 1.78, 0 和 0，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 0.07，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
cash-flows.row.net-income	-24.54	-24.5	-33.3	-45.7	-37.2	-25.5	-26.8	-17.6	-22.8	-14.1	-9.8	0.1
cash-flows.row.depreciation-and-amortization	1.81	1.8	2.8	2.4	2.1	1	0.6	0.4	0.4	0.3	0.4	0.4
cash-flows.row.deferred-income-tax	14.53	-4.5	0	0	0.2	-1.2	-0.2	0.2	-1.9	0	0.7	0
cash-flows.row.stock-based-compensation	3.35	3.3	4.4	5.2	5.1	5.4	4.9	3	1.9	1.2	0.6	0
cash-flows.row.change-in-working-capital	-48.14	-48.1	-33.4	30.5	-16.4	-32.1	21.9	63.5	6.1	-0.8	0.6	-3.9
cash-flows.row.account-receivables	5.31	5.3	-2.6	-1.8	5.3	-4.1	12.5	-14.5	-0.1	0	0.5	-0.3
cash-flows.row.inventory	0	0	0	5.7	-2.9	-0.8	0	4	1	0	-1.1	-3.2
cash-flows.row.account-payables	-0.79	-0.8	-4.2	7	-4.4	1.3	0.8	-0.3	1.4	-0.1	1.1	-0.5
cash-flows.row.other-working-capital	-12.71	-52.7	-26.5	19.6	-14.5	-28.5	8.6	74.4	3.8	-0.7	0.1	0.1
cash-flows.row.other-non-cash-items	-0.82	18.3	-0.5	0	0.3	-0.1	-1.6	0.3	1.9	0.7	2.6	0.4
cash-flows.row.net-cash-provided-by-operating-activities	-53.82	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-0.17	-0.2	-1	-0.9	-2.7	-2.5	-1.7	-1.9	-0.6	-0.6	-0.3	0
cash-flows.row.acquisitions-net	-12.17	0	20.2	0	-41.9	-12.3	0	0	0	0	0	0
cash-flows.row.purchases-of-investments	-22.84	-22.8	-48.4	0	-41.5	-59.3	-117.6	-43.9	0	0	0	0
cash-flows.row.sales-maturities-of-investments	35.01	35	28.2	0	83.4	71.6	110.4	0	0	0	0	0
cash-flows.row.other-investing-activites	12.17	0	-20.2	0	41.9	12.3	0	0	0	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	12	12	-21.2	-0.9	39.2	9.8	-8.9	-45.9	-0.6	-0.6	-0.3	0
cash-flows.row.debt-repayment	0	0	-1	0	0	0	0	0	0	-1.2	-0.2	0
cash-flows.row.common-stock-issued	19.74	19.8	6.9	57.1	9.6	31	47.2	0	15.2	25.8	12	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-financing-activites	0.07	0.1	1.3	2	0.5	1.2	1.3	4.1	0	0	8.6	0.3
cash-flows.row.net-cash-used-provided-by-financing-activities	19.8	19.8	7.2	59.1	10.1	32.2	48.5	4.1	15.2	24.6	20.3	0.3
cash-flows.row.effect-of-forex-changes-on-cash	0.78	0.8	-5.2	-3.2	4.7	-2.1	-1.6	0.6	-0.3	-0.4	-0.2	0.2
cash-flows.row.net-change-in-cash	-21.24	-21.2	-79.1	47.3	8.2	-12.6	37	8.5	0	10.9	14.8	-2.6
cash-flows.row.cash-at-end-of-period	134.97	17.4	38.6	117.8	70.4	62.3	74.9	37.9	29.4	29.3	18.5	3.7
cash-flows.row.cash-at-beginning-of-period	156.21	38.6	117.8	70.4	62.3	74.9	37.9	29.4	29.3	18.5	3.7	6.3
cash-flows.row.operating-cash-flow	-53.82	-53.8	-59.9	-7.7	-45.9	-52.5	-1.1	49.8	-14.4	-12.7	-5.1	-3.1
cash-flows.row.capital-expenditure	-0.17	-0.2	-1	-0.9	-2.7	-2.5	-1.7	-1.9	-0.6	-0.6	-0.3	0
cash-flows.row.free-cash-flow	-53.99	-54	-61	-8.6	-48.6	-54.9	-2.8	47.8	-15	-13.3	-5.3	-3.1

利润表行

Pieris Pharmaceuticals, Inc. 的收入与上期相比变化了 0.653%。据报告, PIRS 的毛利润为 41.03。该公司的营业费用为 56.87，与上年相比变化了 -7.075%. 折旧和摊销费用为 1.78，与上一会计期间相比变化了 -0.782%. 营业费用报告为 56.87，显示-7.075% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长0.636%. 营业收入为 -15.84，与上年相比变化了-0.636%. 净利润的变化率为 -0.215%。去年的净收入为-24.54.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
income-statement-row.row.total-revenue	42.81	42.8	25.9	31.4	29.3	46.3	29.1	25.3	5.8	2.9	5.4	9.9
income-statement-row.row.cost-of-revenue	6.49	1.8	2.8	2.4	46.5	55	0	0	0	0	0	0
income-statement-row.row.gross-profit	36.32	41	23.1	29.1	-17.2	-8.7	29.1	25.3	5.8	2.9	5.4	12.4
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	41.8	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	16.85	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	13.91	13.9	-8.2	-3.7	-3.7	0	1.8	-2.1	0.1	0	0	0
income-statement-row.row.operating-expenses	55.04	56.9	61.2	79.6	63.2	73.4	59.9	39.9	28.6	16.6	12.6	9.3
income-statement-row.row.cost-and-expenses	55.04	58.7	61.2	79.6	63.2	73.4	59.9	39.9	28.6	16.6	12.6	9.3
income-statement-row.row.interest-income	1.85	1.9	0.7	0	0.5	1.7	2	0.2	0	0	0	0
income-statement-row.row.interest-expense	0	0	-10.2	0	0	0	-3.8	1.9	0	0.2	2.7	0.5
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-11.32	-8.7	10.2	6.1	-3.1	1.7	3.8	-2.1	0.1	0	0	0
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	13.91	13.9	-8.2	-3.7	-3.7	0	1.8	-2.1	0.1	0	0	0
income-statement-row.row.total-operating-expenses	-11.32	-8.7	10.2	6.1	-3.1	1.7	3.8	-2.1	0.1	0	0	0
income-statement-row.row.interest-expense	0	0	-10.2	0	0	0	-3.8	1.9	0	0.2	2.7	0.5
income-statement-row.row.depreciation-and-amortization	3.94	1.8	8.2	3.7	2.1	1	0.6	0.4	0.4	0.3	0.4	0.4
income-statement-row.row.ebitda-caps	3.87	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-30.74	-15.8	-43.5	-51.8	-33.9	-27.2	-30.8	-14.6	-22.8	-13.7	-7.2	0.6
income-statement-row.row.income-before-tax	-24.54	-24.5	-33.3	-45.7	-37.1	-25.5	-27.1	-16.5	-22.6	-13.9	-9.8	0.1
income-statement-row.row.income-tax-expense	12.28	0	-2	-2.4	0.2	-1.7	-0.3	1.1	0.2	0.2	0	0.5
income-statement-row.row.net-income	-23.67	-24.5	-31.3	-43.4	-37.2	-23.8	-26.8	-17.6	-22.8	-14.1	-9.8	0.1